Sucampo Pharmaceuticals, a developer of proprietary drugs based on prostones to treat constipation, priced its 3.75 million shares at $11.50 each, 23% below the midpoint of the proposed $14-$16 price range, on Thursday morning. Cowen & Company was the lead...read more
Sucampo Pharmaceuticals, a developer of proprietary drugs based on prostones, announced terms for its IPO Tuesday. The firm is offering 3.8 million shares, including 625K from insiders, at a price range of $14 to $16. Cowen & Company is the lead manager on the...read more
Sucampo Pharmaceuticals, developer of proprietary drugs based on prostones, filed for its IPO on Monday. Banc of America, Deutsche Bank and Leerink Swann & Company are managing the deal for the Bethesda, MD based company. Terms and timing have yet to be...read more
ALERT: Worst weekly perfomers: VisionChina Media, comScore, Sucampo Pharmaceuticals
The following companies were the worst performing IPOs over the last five trading sessions:
...read more
Sucampo Pharmaceuticals prices well below the range
Sucampo Pharmaceuticals, a developer of proprietary drugs based on prostones to treat constipation, priced its 3.75 million shares at $11.50 each, 23% below the midpoint of the proposed $14-$16 price range, on Thursday morning. Cowen & Company was the lead...read more
Pharmaceutical company Sucampo files terms for IPO
Sucampo Pharmaceuticals, a developer of proprietary drugs based on prostones, announced terms for its IPO Tuesday. The firm is offering 3.8 million shares, including 625K from insiders, at a price range of $14 to $16. Cowen & Company is the lead manager on the...read more
Developer of proprietary drugs Sucampo Pharmaceuticals files for IPO
Sucampo Pharmaceuticals, developer of proprietary drugs based on prostones, filed for its IPO on Monday. Banc of America, Deutsche Bank and Leerink Swann & Company are managing the deal for the Bethesda, MD based company. Terms and timing have yet to be...read more